The biochemistry of Alzheimer's disease

Drugs and Aging

Volumn 14, Issue 6, 1999, Pages 437-446

  Stege, Gerard J J ^a   Bosman, Giel J C G M ^a,b  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; MUTANT PROTEIN; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALLELE; ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTE; CELL MEMBRANE; DEMENTIA; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; GENETIC SUSCEPTIBILITY; HUMAN; INFLAMMATION; MICROGLIA; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION; TISSUE NECROSIS;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; HUMANS; MEMBRANE PROTEINS; PRESENILIN-1;

EID: 0032972031     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914060-00004     Document Type: Review

References (106)

1. 1. Rubinstein DC. The genetics of Alzheimer's disease. Prog Neuobiol 1997; 52: 447-54
2. 2. Selkoe DJ. Normal and abnormal biology of the β-amyloid precursor protein. Annu Rev Neurosci 1994; 17: 489-517
3. 3. Hardy J. Alzheimer's disease. Clinical molecular genetics. Clin Geriatr Med 1994; 10:239-47
4. 4. Oliver C, Holland AJ. Down's syndrome and Alzheimer's disease: a review. Psychol Med 1986; 16: 307-22
5. 5. McKee AC, Kosik KS, Kowall NW. Neuritic pathology and dementia in Alzheimer's disease. Ann Neurol 1991; 30: 156-65
6. 6. Wilcock GK, Esiri MM. Plaques, tangles and dementia. J Neurol Sci 1982; 56: 343-56
7. 7. Jellinger KA. The neuropathological diagnosis of Alzheimer disease. J Neural Transm Suppl 1998; 53: 97-118
8. 8. Cummings BJ, Cotman CW. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 1995; 346: 1524-8
9. 9. Van Leeuwen FW, De Kleijn DPV, Van den Hurk HH, et al. Frameshift mutations of β amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 1998; 279: 242-7
10. 10. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing 717VxF β-amyloid precursor protein: Nature 1995; 373: 523-7
11. 11. Kelly JW, The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998; 8: 101-6
12. 12. Cotman CW, Pike CJ, Copani A. β-amyloid neurotoxicity: a discussion of in vitro findings. Neurobiol Aging 1992; 13: 587-90
13. 13. Pike CJ, Burdick D, Walencewicz AJ, et al. Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 1993; 13: 1676-87
14. 14. Yankner BA, Lorenzo A. Amyloid fibril toxicity in Alzheimer's disease and diabetes. Ann N Y Acad Sci 1996; 777: 89-95
15. 15. Wisniewski T, Castano EM, Golabek A, et al. Acceleration of Alzheimer's fibril formation by Apolipoprotein E in vitro. Am J Pathol 1994; 145: 1030-5
16. 16. Inestrosa NC, Alvarez A, Perez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-91
17. 17. Eriksson S, Janciauskiene S, Lannfelt T. Alpha l-antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc Natl Acad Sci USA 1995; 92: 2313-7
18. 18. Campion D, Martin C, Heilig R. et al. The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics 1995; 26: 254-7
19. 19. Masliah E, Iwai A, Mallory M, et al. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol 1996; 148: 201-10
20. 20. Irizarry MC, Tim TW, McNamara M, et al. Characterization of the precursor of the non-Aβ component of senile plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol 1996; 55: 889-95
21. 21. Iwai A, Masliah E, Yoshimato M, et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995; 14:467-75
22. 22. Iwai A, Masliah E, Sundsmo MP, et al. The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease. Brain Res 1996; 720: 230-4
23. 23. Weinreb PH, Zhen W, Poon AW, et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996; 35: 13709-15
24. 24. Kim J. Evidence that the precursor protein of non Aβ component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil. Mol Cells 1997; 7: 78-83
25. 25. Yoshimoto M, Iwai A, Kang D, et al. NACP, the precursor protein of the non-amyloid β/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc Natl Acad Sci USA 1995; 92: 9141-5
26. 26. Iwai A, Yoshimoto M, Masliah E, et al. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. Biochemistry 1995; 34: 10139-45
27. 27. Rohan de Silva HAR, Patel AJ. Presenilins and early-onset familial Alzheimer's disease. Neuroreport 1997; 8: 1-12
28. 28. Lehmann S, Chiesa R, Harris DA. Evidence for a six-transmembrane domain structure of presenilin 1. J Biol Chem 1997; 272: 12047-51
29. 29. Dewji NN, Singer SJ. The seven-transmembrane spanning topography of the Alzheimer disease-related presenilin proteins in the plasma membranes of cultured cells. Proc Natl Acad Sci USA 1997; 94: 14025-30
30. 30. Dewji NN, Do C, Singer SJ. On the spurious endoproteolytic processing of the presenilin proteins in cultured cells and tissue. Proc Natl Acad Sci USA 1997; 94: 14031-6
31. 31. Hendriks L, Thinakuran G, Harris CL, et al. Processing of presenilin 1 in brains of patients with Alzheimer's disease and controls. Neuroreport 1997; 8: 1717-21
32. 32. Kovacs DM, Fausett HJ, Page KJ, et al. Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells. Nat Med 1496; 2: 224-9
33. 33. Xia W, Zhang J, Perez R, et al. Interaction between amyloid precursor protein and presenilins in mammalian cells, implications for the pathogenesis of Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 8208-13
34. 34. Li J, Xu M, Zhou Z, et al. Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation. Cell 1997; 90: 917-27
35. 35. Haass C, Presenilins: genes for life and death. Neuron 1997; 18: 687-90
36. 36. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997; 3: 67-72
37. 37. Lamb BT. Presenilins, amyloid-β and Alzheimer's disease. Nat Med 1997; 3: 28-9
38. 38. Wolozin B, Iwasaki K, Vito P, et al. Participation of Presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996; 274: 1710-13
39. 39. Kim T-W, Pettingell WH, Jung Y-K, et al. Alternative cleavage of Alzheimer-associated presenilins during apoplosis by a caspase-3 family protease. Science 1997; 277: 373-6
40. 40. Braak H, Braak F, Bohl J, et al. Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Neurosci Lett 1996; 210; 87-90
41. 41. Braak H, Braak E, Yilmazer D, et al. Pattern of brain destruction in Parkinson's and Alzheimer's diseases. J Neural Transm 1996; 103: 455-90
42. 42. Lovestone S, Reynolds CH. The phosphorylation of tau: a critical singe in neurodevelopment and neurodegenerative processes. Neuroscience 1997; 78: 309-24
43. 43. Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau prolein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997; 323: 577-91
44. 44. Sergeant N, David JP, Goedert M, et al. Two-dimensional characterization of paired helical filament-tau from Alzheimer's disease: demonstration of an additional 74-kDa component and age-related biochemical modifications. J Neurochem 1997; 69: 834-44
45. 45. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-5
46. 46. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47: 387-400
47. 47. Higgins GA, Large CM, Rupniak HT, et al. Apolipoprotein E and Alzheimer's disease: a review of recent studies. Pharmacol Biochem Behav 1997; 56: 675-85
48. 48. Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 1997; 48: 139-47
49. 49. Betard C, Robitaille Y, Gee M, et al. Apo E allele frequencies in Alzheimer's disease, Lewy body dementia, Alzheimer's disease with cercbrovascular disease and vascular dementia. Neuroreport 1994; 5: 1893-6
50. 50. Weisgraber KH, Pitas RE, Mahley RW. Lipoproteins, neurobiology, and Alzheimer's disease: structure and function of apolipoprotein E. Curr Opin Struct Biol 1994; 4: 507-15
51. 51. Han S-H, Einstein G, Weisgraber KH, et al. Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study. J Neuropathol Exp Neurol 1994; 53:535-44
52. 52. Soto C, Castano EM, Prelli F, et al. Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, gelsolin and AA amyloids. FEBS Lett 1995; 371: 110-14
53. 53. Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997, 388: 878-81
54. 54. Naiki H, Gejyo F, Nakakuki K. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1997; 36: 6243-50
55. 55. Aleshkov S, Abraham CR, Zannis VI. Imeraction of nascent apoE2, apoE3, and apoE4 isolorms expressed in mammalian cells with amyloid peptide beta (1-40). Biochemistry 1997; 36: 10571-80
56. 56. LaDu MJ, Falduto MT, Manelli AM, et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem 1994; 269: 23403-6
57. 57. Duff K. Alzheimer transgenic mouse models come of age. Trends Neurosci 1997; 20: 279-80
58. 58. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of eytokine TGF-β1 in transgenic mice in Alzheimer's disease. Nature 1997; 389: 603-6
59. 59. Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 1550-5
60. 60. Irizarry MC, Soriano F, McNamara M, et al. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F(PDAPP) transgenic mouse. J Neurosci 1997; 17: 7053-9
61. 61. Irizarry MC, McNamara M, Fedorchak K, et al. APPSw transgenic mice develop age related A beta deposits and neuropil abnormalities, but no neuronal loss in CAI. J Neuropathol Exp Neurol 1997; 56: 965-73
62. 62. Duff K, Eckman C, Zehr C, et al. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383: 710-3
63. 63. Borehelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996; 17: 1005-13
64. 64. Borchelt DR, Ratovitski T, van Lare J, et al. Accelerated amyloid depositions in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19: 939-45
65. 65. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998; 4:97-100
66. 66. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mite. Science 1996; 274: 99-102
67. 67. Arendt T, Holzer M, Fruth R, et al. Paired helical filament-like phosphorylation of tau, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 1995, 69: 691-8
68. 68. Su JH, Anderson AJ, Cummings BJ, et al. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994; 5: 2529-33
69. 69. Dragunow M, Faull RLM, Lawlor P, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport 1995; 6: 1053-7
70. 70. Lassmann H, Bancher C, Breitschopf H, et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol 1995; 89: 35-41
71. 71. De la Monte SM, Sohn YK, Wands JR. Correlates of p53-and Fas (CD95)-mediated apoplosis in Alzheimer's disease. J Neurol Sci 1997; 152:73-83
72. 72. Su JH, Satou T, Anderson AJ, et al. Up-regulalion of Bcl-2 is associated with neuronal DNA damage in Alzheimer's disease. Neuroreport 1996; 7: 437-40
73. 73. Forloni G, Chiesa R, Smiroldo S, et al. Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25-35. Neuroreport 1993; 4: 523-6
74. 74. Loo DT, Copani A, Pike CJ, et al. Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 1993; 90: 7951-5
75. 75. Anderson AJ, Pike CJ, Cotman CW. Differential induction of immediate early gene proteins in cultured neurons by beta-amyloid (Abeta): association of c-Jun with Abeta-induced aoptosis. J Neurochem 1995; 65: 1487-98
76. 76. Dupont-Wallois L, Sautiere PE, Cocquerelle C, et al. Shift from fetal-type to Alzheimer-type phosphorylated tau proteins in SKNSH SY 5Y cells treated with okadaic acid. FEBS Lett 1995; 357: 197-201
77. 77. Rozemuller JM, Stam FC, Eikelenboom P. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci Lett 1990; 119: 75-8
78. 78. McGeer PL, Kawamata T, Walker DC, et al. Microglia in degenerative neurological disease. Glia 1993; 7: 84-92
79. 79. Van Muiswinkel FL, Veerhuis K, Eikelenboom P. Amyloid β protein (Aβ) primes cultured rat microglial cells for an enhanced phorhol-myristate-acetate induced respiratory burst activity. J Neurochem 1996, 66: 2468-76
80. 80. Sheng JG, Ito K, Skinner RD, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996; 17: 761-6
81. 81. London JA, Biegel D, Pachter JS. Neurocytopathic effects of β-amyloid-stimulated monocytes: a potential mechanism for central nervous system damage in Alzheimer disease. Proc Natl Acad Sci USA 1996; 93: 4147-52
82. 82. Lue L-F, Bruchova L, Civin WH, et al. Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 1996; 55: 1083-8
83. 83. Bredesen DE. Neural apoptosis. Ann Neurol 1995; 38: 839-51
84. 84. Shioi J, Pangalos MN, Ripellino JA, et al. The Alzheimer amyloid precursor proteoglycan (appican) is present in brain and is produced by astrocytes but not by neurons in primary neural cultures. J Biol Chem 1995; 270: 11839-44
85. 85. Lee RKK, Wurtman RJ. Metabotropic glutamate receptors increase amyloid precursor protein processing in astrocytes: inhibition by cyclic AMP. J Neurochem 1997; 68: 1830-5
86. 86. Renkawek K, Voorter CEM, Bosman GJCGM, et al. Expression of αB-crystallin in Alzheimer's disease. Acta Neuropathol 1994; 87: 155-60
87. 87. Gehrmann J, Matsumoto Y, Kreutzberg GW. Microglia: intrinsic immunoeffector cell of the brain. Brain Res Rev 1995; 20: 269-87
88. 88. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19: 312-8
89. 89. Wisniewski HM, Vorbrodt AW, Wegiel J, et al. Ultrastructure of the cells forming amyloid fibers in Alzheimer disease and scrapie. Am J Med Genet 1990; 7: 287-97
90. 90. McGeer PL, Schulzer M, McGeer EG. Arthritis and antiinflammatury agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-32
91. 91. Chen S, Frederickson RCA, Brunden KR. Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches. Neurobiol Aging 1996; 17: 781-7
92. 92. Velazquez P, Cribbs DH, Poulos TL, et al. Aspartate residue 7 in amyloid beta protein is critical for classical complement pathway activation: implications for Alzheimer's disease progress. Nat Med 1997; 3: 77-9
93. 93. Paresce DM, Ghosh RN, Maxfield FR. Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta protein via a scavenger receptor. Neuron 1996; 17; 553-65
94. 94. Busman GJCGM, Bartholomeus IGP, De Grip WJ. Cellular aging and Alzheimer's disease: membrane-related events as clues to primary mechanisms. Gerontology 1991; 37: 95-112
95. 95. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of alzheimer's disease. Trends Neurosci 1993; 16:403-9
96. 96. Bodovitz S, Klein WL. Cholesterol modulates a-secretase cleavage of amyloid precursor protein. J Biol Chem 1996; 271: 4436-40
97. 97. Bullido MJ, Munoz-Fernandez MA, Recuero M, et al. Alzheimer's amyloid precursor protein is expressed on the surface of hematopoietic cells upon activation. Biochim Biophys Acta 1996; 1313:54-62
98. 98. Cowburn RF, O'Neill C, Fowler CJ. Membrane alterations in Alzheimer's disease and aging Trends Neurosci 1995; 18: 483-4
99. 99. Arispe N, Pollard HB, Rojas E. β-amyloid Ca2-t-channel hypothesis for neuronal death in Alzheimer disease. Mol Cell Biochem 1994; 140; 119-25
100. 100. Landfield PW, Thibault O, Mazzanti ML, et al. Mechanisms of neuronal death in hrain aging and alzheimer's disease: role of endocrine-mediated calcium dyshomeostasis. J Neurobiol 1992; 23: 1247-60
101. 101. Wang H-Y, Friedman E. Receptor-mediated activation of G proteins is reduced in postmortem brains from Alzheimer's disease patients. Neurosci Lett 1994; 173; 37-9
102. 102. Shimohama S, Sasaki Y, Fujimoto S, et al. Phospholipase C isozymes in the human brain and their changes in Alzheimer's disease. Neuroscience 1998; 82: 999-1007
103. 103. Snow AD, Sekiguchi R, Nochlin P, et al. An important role of heparin sulfate proteoglycan (perlecan) in a model system for the deposition and persistence of fibrillar A beta amyloid in rat brain. Neuron 1994; 12: 219-34
104. 104. Goedert M, Jakes R, Spillantini MG, et al. Assembly of microbutule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosnminoglycans. Nature 1996; 383; 550-3
105. 105. Saitoh T, Masliah E, Baum L, et al. Degradation of proteins in the membrane-eytoskeleton complex in Alzheimer's disease. Ann N Y Acad Sci 1992; 674: 180-92
106. 106. Bosman GJCGM, Van Workum FPA, Renkawek K, et al. Proteins immunologically related to erythrocyte anion transporter band 3 are altered in brain areas affected by Alzheimer's disease. Acta Neuropathol 1993; 86: 353-9